Spotlight on Bevacizumab in Advanced Colorectal Cancer, Breast Cancer, and Non-Small Cell Lung Cancer

Abstract

Bevacizumab (Avastin™) is a humanized recombinant antibody that prevents vascular endothelial growth factor (VEGF) receptor binding, and inhibits angiogenesis and tumor growth. In patients receiving an irinotecan plus fluorouracil/leucovorin (IFL) regimen for first-line treatment of metastatic colorectal cancer, the addition of bevacizumab significantly… (More)
DOI: 10.2165/00063030-200620030-00007

Topics

  • Presentations referencing similar topics